Key result
Baseline ECG r′-wave base duration and β-angle predict positive flecainide challenge with ~0.78 AUC in Brugada.
Why the study?
Flecainide challenge testing for Brugada syndrome carries potential risks, and while baseline ECG markers may refine pre-test risk stratification, the relationship of baseline r′-wave triangle base duration and beta-angle with oral flecainide challenge positivity remained uncertain.
Are baseline r′-wave triangle base duration and beta-angle associated with oral flecainide challenge positivity in patients undergoing diagnostic evaluation for Brugada syndrome?
Observational (n=40)
No
Are baseline r′-wave triangle base duration and beta-angle associated with oral flecainide challenge positivity in patients undergoing diagnostic evaluation for Brugada syndrome?
Baseline r′-wave triangle base duration and beta-angle on standard 12-lead ECG show moderate discriminatory performance for predicting a positive oral flecainide challenge test in suspected Brugada syndrome.
Answers are grounded in this paper and cite their sources.
Baseline ECG markers may support pre-test BrS risk stratification; leaves open whether they should alter flecainide challenge decisions.
Background: Electrocardiographic markers, including the r′-wave triangle base duration and beta-angle, have been proposed as adjunctive indicators of Brugada syndrome (BrS). As flecainide challenge testing (FCT) carries potential risks, baseline ECG predictors may refine pre-test risk stratification, although their relationship with oral flecainide challenge positivity remains uncertain. Objective: To evaluate whether baseline r′-wave triangle base duration and beta-angle were associated with FCT positivity. Methods: This retrospective, single-center review included consecutive patients who underwent oral flecainide challenge within a historical institutional diagnostic pathway between September 2023 and September 2025. Baseline right-precordial ECG measurements, including r′-wave triangle base duration and beta-angle, were obtained from archived standard 12-lead tracings. The primary outcome was FCT positivity, defined as the emergence of a diagnostic type 1 Brugada pattern Result: Among 40 included patients, 28 had a positive oral flecainide challenge result and 12 had a negative result. In exploratory analyses, larger baseline β-angle and longer r′-wave triangle base duration were associated with oral flecainide challenge positivity. Mean β-angle was 36.07° ± 15.86° in positive versus 21.83° ± 10.72° in negative challenges (p=0.007); mean r′-wave triangle base duration was 161.6 ± 92.8 ms versus 81.6 ± 38.0 ms, respectively (p<0.001). ROC analysis showed moderate discriminatory performance (AUC 0.756 for β-angle, 0.769 for r′-wave). Sample-derived thresholds of 27.5° and 2.625 mm (105 ms) yielded sensitivity of 71.4% and specificity of 83.3%. A combined model incorporating both parameters showed an AUC of 0.780 (95% CI, 0.635–0.924), with 75.0% sensitivity and 83.3% specificity at the Youden-optimal threshold. Conclusion: Baseline r′-wave triangle base duration and beta-angle were associated with FCT positivity. These findings support further prospective investigation using standardized ECG acquisition and contemporary provocation protocols.
No takes yet. Share an insight, caveat, or question.
Raharjo et al. (2026) conducted an observational in Brugada syndrome (n=40). Baseline r′-wave triangle base duration and beta-angle vs. Negative oral flecainide challenge result was evaluated on Oral flecainide challenge positivity, defined as the emergence of a diagnostic type 1 Brugada pattern (AUC 0.780, 95% CI 0.635-0.924, p=<0.001). Baseline r′-wave triangle base duration and β-angle predicted oral flecainide challenge positivity in suspected Brugada syndrome with a combined AUC of 0.780.
Synapse has enriched 10 related papers. Consider them for comparative context: